Evidence map›Paper›PMID 37475863›Full record

ArticleFrontiers in immunology2023

An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.

Santeri Pakola, Dafne C A Quixabeira, Tatiana V Kudling, James H A Clubb, Susanna Grönberg-Vähä-Koskela, Saru Basnet, Elise Jirovec, Victor Arias, Lyna Haybout, Camilla Heiniö and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Cytokines and cancer-associated fibroblasts.Journal of hematology & oncology · 2026
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Santeri PakolaCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Dafne C A QuixabeiraCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Tatiana V KudlingCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
James H A ClubbCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Susanna Grönberg-Vähä-KoskelaCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Saru BasnetCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Elise JirovecCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Victor AriasCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Lyna HayboutCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Camilla HeiniöCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Joao M SantosCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Victor Cervera-CarrasconCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Riikka HavunenCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Marjukka AnttilaPathology, Finnish Food Authority, Helsinki, Finland.
Akseli HemminkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIBiocenter Finland · FIFinnish Food Authority · FIHelsinki University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only curative treatment for PDAC is surgery, but most patients are diagnosed with metastatic disease and thus outside the scope of surgery. The majority of metastatic patients receive chemotherapy, but responses are limited. New therapeutics are thus urgently needed for PDAC. One major limitation in treating PDAC has been the highly immunosuppressive tumor microenvironment (TME) which inhibits anti-cancer immune responses. We have constructed an oncolytic adenovirus coding for a variant the interleukin 2 molecule, Ad5/3-E2F-d24-vIL2 (also known as TILT-452, and "vIL-2 virus"), with preferential binding to IL-2 receptors on the surface of effector lymphocytes over T regulatory cells (T regs). In the present study this virus was evaluated in combination with nab-paclitaxel and gemcitabine chemotherapy in Panc02 mouse model. Ad5/3-E2F-d24-vIL2 showed marked PDAC cell killing

Indexed as

Adenoviridae InfectionsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAdenoviridaeAnimalsCell Line, TumorCytokinesFibroblastsGemcitabineInterleukin-2LymphocytesMiceTumor MicroenvironmentCytokinesGemcitabineInterleukin-2adenoviruschemotherapyimmunotherapyinterleukin 2oncolytic virus

Identifiers

PMID37475863
PMCPMC10354511
OpenAlexW4383198690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.